Abstract
Recent years have seen the development of the concept of combination therapy for treating severe fungal sepsis. The advantages of this approach are a potential improvement in patient survival and a reduction in the chance of resistance developing to each of the single agents. The disadvantage is that combining drugs may increase the chance of toxicity. Mycograb® is a genetically recombinant antibody against fungal heat shock protein 90 (hsp90) which is poised to become the mainstay of combination therapy. This paper presents data on how hsp90 is important to fungi and what role it might play in human disease with possible interactions with interleukin 6 and nitric oxide. There is discussion of preclinical data demonstrating synergy in vitro between Mycograb® and amphotericin B and caspofungin. The progress of Mycograb® through a Phase II pharmacokinetic study when used in escalating doses with a liposomal amphotericin B preparation has also been reviewed. The concepts behind a Phase II pivotal study, where Mycograb® or a placebo was given in combination with a liposomal amphotericin B drug for five days for the treatment of disseminated candidiasis are discussed.
Keywords: mycograb, hsp, candidiasis, amphotericin b, interleukin, map kinases, nitric oxide, immunotherapy
Current Molecular Medicine
Title: Human Recombinant Antibody to HSP90: A Natural Partner in Combination Therapy
Volume: 5 Issue: 4
Author(s): R. C. Matthews and J. P. Burnie
Affiliation:
Keywords: mycograb, hsp, candidiasis, amphotericin b, interleukin, map kinases, nitric oxide, immunotherapy
Abstract: Recent years have seen the development of the concept of combination therapy for treating severe fungal sepsis. The advantages of this approach are a potential improvement in patient survival and a reduction in the chance of resistance developing to each of the single agents. The disadvantage is that combining drugs may increase the chance of toxicity. Mycograb® is a genetically recombinant antibody against fungal heat shock protein 90 (hsp90) which is poised to become the mainstay of combination therapy. This paper presents data on how hsp90 is important to fungi and what role it might play in human disease with possible interactions with interleukin 6 and nitric oxide. There is discussion of preclinical data demonstrating synergy in vitro between Mycograb® and amphotericin B and caspofungin. The progress of Mycograb® through a Phase II pharmacokinetic study when used in escalating doses with a liposomal amphotericin B preparation has also been reviewed. The concepts behind a Phase II pivotal study, where Mycograb® or a placebo was given in combination with a liposomal amphotericin B drug for five days for the treatment of disseminated candidiasis are discussed.
Export Options
About this article
Cite this article as:
Matthews C. R. and Burnie P. J., Human Recombinant Antibody to HSP90: A Natural Partner in Combination Therapy, Current Molecular Medicine 2005; 5 (4) . https://dx.doi.org/10.2174/1566524054022594
DOI https://dx.doi.org/10.2174/1566524054022594 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Thioredoxin System Modulation by Plant and Fungal Secondary Metabolites
Current Medicinal Chemistry Allergic Bronchopulmonary Aspergillosis: AllA Radiologist Needs To Know
Current Pediatric Reviews Myeloproliferative Neoplasms Including Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis, Chronic Neutrophilic Leukemia, and Myeloproliferative Neoplasm, Unclassifiable
Current Cancer Therapy Reviews Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent
Current Drug Safety Immunophenotype of Vitamin D Receptor Polymorphism Associated to Risk of HIV-1 Infection and Rate of Disease Progression
Current HIV Research Design, Synthesis, and Structure-Activity Relationship Study of Peroxisome Proliferator-Activated Receptor (PPAR) δ-Selective Ligands
Current Medicinal Chemistry Atorvastatin Sensitises Vascular Smooth Muscle Cells, but not Endothelial Cells, to TNF-α-induced Cell Death
Current Pharmaceutical Design Gene Therapy for Arthritis
Current Drug Targets Editorial: Current Strategies for Drug Discovery Targeting Neurological Autoimmune Diseases
Central Nervous System Agents in Medicinal Chemistry Hepatocyte Growth Factor is a Potential Lymphangiogenic Factor; Clinical Implications
Current Signal Transduction Therapy Adult Stem Cells for Cartilage Tissue Engineering and Regeneration
Current Rheumatology Reviews Editorial [Hot Topic: Latest Developments in Pharmaceutical Design of Arachidonic Acid Metabolites: Prostaglandins, Thromboxanes, Hepoxilins and Isoprostanes (Executive Editors: J.-M. Dogne and K.-H. Ruan )]
Current Pharmaceutical Design C-type Lectin Receptor: Old Friend and New Player
Medicinal Chemistry Nano Technological Approaches for Anti-tumour Therapy: Opportunities and Challenges
Nanoscience & Nanotechnology-Asia Recent Advances in Neuro-Endocrine-Immune Interactions in the Pathophysiology of Rheumatoid Arthritis
Current Rheumatology Reviews Immune Mechanisms and Novel Pharmacological Therapies of Acute Kidney Injury
Current Drug Targets Genetics and Epigenetics Mechanism in the Pathogenesis of Behçet’s Disease
Current Rheumatology Reviews Meet Our Associate Editor
Current Molecular Medicine Monoclonal Antibodies as a Tool for Structure-Function Studies of the MDR1-P-Glycoprotein
Current Protein & Peptide Science Cerebral Aneurysm as an Exacerbating Factor in Stroke Pathology and a Therapeutic Target for Neuroprotection
Current Pharmaceutical Design